Become part of the next generation of EASL’s leadership!
Are you deeply engaged in hepatology and science and ready to get involved in EASL’s governance? EASL is now looking to fill the following positions: EASL Vice-Secretary Three Educational Committee Members Three Policy and Public Health…
On Rare Disease Day, we honour the many, the strong, the proud
EASL honours Rare Disease Day, taking place this Sunday, 28 February. An estimated 300 million people globally are affected by rare diseases – diseases of which 6,000 have been identified.
Global survey shows impact of COVID-19 response on hepatitis prevention care and treatment
In the wake of the COVID-19 pandemic, several liver associations recommended certain changes in hepatitis clinical care to mitigate transmission risks for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the causative agent…
Honouring women in hepatology this International Day of Women and Girls in Science
On International Day of Women and Girls in Science, 11 February, EASL honours the many women making waves in our field of hepatology. As highlighted by the UN, both science and gender…
EASL policy statement on the use of COVID-19 vaccines in people with chronic liver disease, hepatobiliary cancer, and liver transplant recipients
9 February 2021 By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100…
New breakthrough in advanced HCC
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in…
Global survey reveals heavy toll of COVID-19 first wave on liver cancer care
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark…